US · Healthcare · Biotechnology
EPS came in at -0.18 against a street estimate of -0.09 — a miss of 100.0%.
Analysts rate NRX Pharmaceuticals Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $38.50.
| Fund | Stake |
|---|---|
| B Group, Inc | 9.45% |
| Vanguard Capital Management, LLC | 3.74% |
| Columbia Mgmt Investment Advisers, LLC | 2.15% |
| Balyasny Asset Management LLC | 2.06% |
| Citadel Advisors Llc | 1.57% |
| AdvisorShares Investments, LLC | 1.52% |
| Commonwealth Equity Services, LLC | 1.05% |
| UBS Group AG | 0.98% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for NRX Pharmaceuticals Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.